Kuros Biosciences Ag Stock Performance
| CSBTF Stock | USD 38.34 0.00 0.00% |
On a scale of 0 to 100, Kuros Biosciences holds a performance score of 11. The company secures a Beta (Market Risk) of 0.14, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Kuros Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Kuros Biosciences is expected to be smaller as well. Please check Kuros Biosciences' treynor ratio, as well as the relationship between the downside variance and kurtosis , to make a quick decision on whether Kuros Biosciences' current price movements will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Kuros Biosciences AG are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Kuros Biosciences reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 28.4 M | |
| Total Cashflows From Investing Activities | -374 K | |
| Free Cash Flow | -5.8 M |
Kuros |
Kuros Biosciences Relative Risk vs. Return Landscape
If you would invest 2,830 in Kuros Biosciences AG on September 28, 2025 and sell it today you would earn a total of 1,004 from holding Kuros Biosciences AG or generate 35.48% return on investment over 90 days. Kuros Biosciences AG is currently producing 0.5307% returns and takes up 3.6145% volatility of returns over 90 trading days. Put another way, 32% of traded pink sheets are less volatile than Kuros, and 90% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Kuros Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kuros Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Kuros Biosciences AG, and traders can use it to determine the average amount a Kuros Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1468
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CSBTF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Kuros Biosciences is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kuros Biosciences by adding it to a well-diversified portfolio.
Kuros Biosciences Fundamentals Growth
Kuros Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Kuros Biosciences, and Kuros Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kuros Pink Sheet performance.
| Return On Equity | -0.14 | |||
| Return On Asset | -0.0667 | |||
| Profit Margin | (0.74) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | 40.53 M | |||
| Shares Outstanding | 36.54 M | |||
| Price To Earning | 0.33 X | |||
| Price To Book | 0.79 X | |||
| Price To Sales | 4.63 X | |||
| Revenue | 13.81 M | |||
| EBITDA | (5.29 M) | |||
| Cash And Equivalents | 28.62 M | |||
| Cash Per Share | 0.87 X | |||
| Total Debt | 2.21 M | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 2.23 X | |||
| Cash Flow From Operations | (5.45 M) | |||
| Earnings Per Share | (0.24) X | |||
| Total Asset | 91.34 M | |||
| Retained Earnings | (37 M) | |||
| Current Asset | 18 M | |||
| Current Liabilities | 2 M | |||
About Kuros Biosciences Performance
By analyzing Kuros Biosciences' fundamental ratios, stakeholders can gain valuable insights into Kuros Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Kuros Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kuros Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. KUROS BIOSCIENCES operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 58 people.Things to note about Kuros Biosciences performance evaluation
Checking the ongoing alerts about Kuros Biosciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Kuros Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kuros Biosciences appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 13.81 M. Net Loss for the year was (7.54 M) with profit before overhead, payroll, taxes, and interest of 10.07 M. | |
| Kuros Biosciences AG has accumulated about 28.62 M in cash with (5.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.87. | |
| Roughly 35.0% of the company shares are held by company insiders |
- Analyzing Kuros Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kuros Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Kuros Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kuros Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kuros Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kuros Biosciences' pink sheet. These opinions can provide insight into Kuros Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Kuros Pink Sheet analysis
When running Kuros Biosciences' price analysis, check to measure Kuros Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kuros Biosciences is operating at the current time. Most of Kuros Biosciences' value examination focuses on studying past and present price action to predict the probability of Kuros Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kuros Biosciences' price. Additionally, you may evaluate how the addition of Kuros Biosciences to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |